Background: Silorimus-eluting stent (SES) lower the amount of intimal hyperplasia and significantly improved clinical outcome in short lesions. Target lesion length is an independent predictor of in-stent restenosis in bare metal stent era. We evaluated the clinical outcomes of the long lesion coverage with SES. Method and results: We implanted long SES stents (>40 mm in length) in 72 type C lesions in 72 patients. The average length of the implanted stents were 58짹14mm (41-112 mm) in length and 2.2 stents were implanted in each patient. No adverse events were observed during procedure and hospital stay. One patient had a subacute thrombosis 50 days after discharge. At 6 months follow up, 3 patients (9.4%) had target lesion revascularization and angiographic binary restenosis was 6.7%. QCA findings were as below. Conclusions: Long lesion coverage with SES stent is feasible with a favorable clinical outcome in clinical practice.